Biolipox completes aquisition from Inflazyme

Biolipox completes aquisition from Inflazyme

Biolipox - with whom Orexo has reached an agreement under which Orexo will
aquire Biolipox - completes the previously announced acquisition of the main
part of the Canadian biopharma company Inflazymes research- and development
assets.

For detailed information, visit www.biolipox.com. 


For more information, please contact:

Torbjörn Bjerke, President and CEO, Biolipox AB
+46 (0)708-66 19 90, e-mail: torbjorn.bjerke@biolipox.com
Claes Wenthzel, Executive VP and CFO, Orexo AB
+46 (0)18 780 88 44, +46 (0)708-62 01 22 , e-mail: claes.wenthzel@orexo.com


TO THE EDITORS 

About Orexo 

Orexo is a pharmaceutical company which focuses on identifying suboptimal
therapeutic characteristics of existing products and developing more efficient
and effective delivery methods for them. By combining approved active substances
with Orexo's drug delivery technologies it is possible to significantly enhance
their therapeutic value, such as providing quicker onset of action or ease of
administration. This business model is aimed at bringing products to market
faster with lower development risk and costs. 

Orexo, which has its global headquarters and development laboratories in Sweden,
currently operates across the world through development, licensing and
distribution agreements in all major markets. 

Orexo has a balanced portfolio with two products on the market, three in
registration and/or late stage clinical phase, one in clinical phase I, one in
formulation phase and two in early development phase. 

Orexo is listed on the Nordic List at the OMX Nordic Exchange Stockholm, Mid Cap
(ticker: ORX). 

www.orexo.com 

About Biolipox 

Biolipox is a Swedish research-intense pharmaceutical company that focuses on
developing novel, effective drugs for treating respiratory diseases and other
inflammatory diseases, such as asthma, chronic obstructive pulmonary disease
(COPD), rhinitis (hay fever), pain and arthritis (inflammatory joint diseases).
By drawing on its knowledge in the inflammatory research area, particularly
arachidonic acid metabolism, Biolipox has created a portfolio of potential
blockbusters in these therapeutic areas. The company has 52 employees and is
owned by Health Cap, Apax Partners, Sofinnova Partners, SLS Venture, Crédit
Agricole Private Equity, Auriga Partners and the scientific founders. 

www.biolipox.com